Inogen Recognized as one of the Fastest Growing Companies in North America according to Deloitte’s 2017 Technology Fast 500™

Achieved 169% Revenue Growth between 2013 and 2016

GOLETA, Calif.–(BUSINESS WIRE)–Inogen,
Inc. (NASDAQ: INGN),
a medical technology company offering innovative respiratory products
for use in the homecare setting, today announced it was included on
Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing
technology, media, telecommunications, life sciences and energy tech
companies in North America. This is the fourth consecutive year that
Inogen has been named to the list. Inogen grew annual revenues from
$75.4M to $202.8M, or 169%, between 2013 and 2016.

Inogen’s President and CEO, Scott Wilkinson, attributes the revenue
growth to increased demand for the company’s innovative products and its
continued leadership in portable oxygen therapy solutions. “It is truly
an honor to be named to Deloitte’s Technology Fast 500™ for the fourth
straight time. This is evidence of the growth in awareness of our
portable oxygen therapy solutions and an increase in the adoption of
portable concentrators in the oxygen market. The increase in revenues in
our consumer and business sales channels is a direct result of these
factors. The knowledge that there are millions of patients worldwide
whose lives can be improved through use of our products gives us bright
hope for the continued success of Inogen,” said Wilkinson.

About Deloitte’s 2017 Technology Fast 500™
Deloitte’s
Technology Fast 500 provides a ranking of the fastest growing
technology, media, telecommunications, life sciences and energy tech
companies — both public and private — in North America. Technology Fast
500 award winners are selected based on percentage fiscal year revenue
growth from 2013 to 2016.

In order to be eligible for Technology Fast 500 recognition, companies
must own proprietary intellectual property or technology that is sold to
customers in products that contribute to a majority of the company’s
operating revenues. Companies must have base-year operating revenues of
at least $50,000 USD, and current-year operating revenues of at least $5
million USD. Additionally, companies must be in business for a minimum
of four years and be headquartered within North America.

As used in this document, “Deloitte” refers to one or more of Deloitte
Touche Tohmatsu Limited, a UK private company limited by guarantee
(“DTTL”), its network of member firms, and their related entities. DTTL
and each of its member firms are legally separate and independent
entities. DTTL (also referred to as “Deloitte Global”) does not provide
services to clients. In the United States, Deloitte refers to one or
more of the US member firms of DTTL, their related entities that operate
using the “Deloitte” name in the United States and their respective
affiliates. Certain services may not be available to attest clients
under the rules and regulations of public accounting. Please see www.deloitte.com/about
to learn more about our global network of member firms.

Inogen has used, and intends to continue to use, its Investor Relations
website, http://investor.inogen.com/,
as a means of disclosing material non-public information and for
complying with its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.

Use of Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
concerning awareness of Inogen’s products and the effect of such
awareness on future financial performance or trends and growth
opportunities affecting Inogen. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including, but not
limited to, risks that Inogen will not realize anticipated revenue and
that future results could be materially different from any future
results expressed or implied by these forward-looking statements. In
addition, Inogen’s business is subject to numerous additional risks and
uncertainties, including, among others, risks relating to market
acceptance of its products; competition; its sales, marketing and
distribution capabilities; its planned sales, marketing, and research
and development activities; interruptions or delays in the supply of
components or materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business and operating results are contained in Inogen’s Annual
Report on Form 10-K for the year ended December 31, 2016 and in Inogen’s
subsequent reports on Form 10-Q and Form 8-K, including Inogen’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.

About Inogen
Inogen is innovation in oxygen therapy. We are
a medical technology company that develops, manufactures and markets
innovative oxygen concentrators used to deliver supplemental long-term
oxygen therapy to patients suffering from chronic respiratory
conditions. For more information, please visit www.inogen.com.

Contacts

Inogen
Investor Relations Contact:
Matt Bacso, CFA
mbacso@inogen.net
or
Media
Contact:
Byron Myers, 805-562-0503